Human lactobacilli as supplementation of clindamycin to patients with bacterial vaginosis reduce the recurrence rate; a 6-month, double-blind, randomized, placebo-controlled ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2008-01-15

AUTHORS

Per-Göran Larsson, Babill Stray-Pedersen, Kjeld R Ryttig, Stig Larsen

ABSTRACT

BackgroundThe primary objective of this study was to investigate if supplementary lactobacilli treatment could improve the initial cure rate after vaginal clindamycin therapy, and secondly, if lactobacilli as repeated adjunct treatment during 3 menstrual cycles could lengthen the time to relapse after initial cure.MethodsWomen (n = 100) with bacterial vaginosis diagnosed by Amsel criteria were after informed consent offered vaginal clindamycin therapy followed by vaginal gelatine capsules containing either 109 freeze-dried lactobacilli or identical placebo capsules for 10 days during 3 menstrual cycles in a double-blind, randomized, placebo-controlled trial.ResultsThe initial intent to treat (ITT) analysis for the one-month cure rate was 64% in the lactobacilli group and 78% in the placebo group (p > 0.05). However, any patient with missing or unclassified smears at the initial visit who continued the study and whose next smear indicated a cure was included in the cured group; the study also excluded two of the patients in the lactobacilli group who reported that they did not take any vaginal capsules. With consideration to these population changes, the initial cure rate would be 77% in the lactobacilli group. The 76 cured women were followed for 6 menstrual cycles or until relapse within that time span. At the end of the study, 64.9% (24/37) of the lactobacilli treated women were still BV-free compared to 46.2% (18/39) of the placebo treated women. Comparison of the two groups regarding "Time from cure to relapse" was statistically significant (p = 0.027) in favour of the lactobacilli treatment. Adjuvant therapy with lactobacilli contributed significantly to avoidance of relapse with a proportional Hazard Risk ratio (HR) of 0.73 (0.54–0.98) (p < 0.05)ConclusionThe study shows that supplementary treatment combining two different strains of probiotic lactobacilli does not improve the efficacy of BV therapy during the first month of treatment, but for women initially cured, adjunct treatment of lactobacilli during 3 menstrual cycles lengthens the time to relapse significantly in that more women remained BV free at the end of the 6-month follow up.Trial registration numberISRCTN62879834 More... »

PAGES

3

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/1472-6874-8-3

DOI

http://dx.doi.org/10.1186/1472-6874-8-3

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1005792714

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/18197974


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Administration, Intravaginal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Administration, Oral", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Anti-Bacterial Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Clindamycin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Combined Modality Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Confidence Intervals", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Double-Blind Method", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Follow-Up Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lactobacillus", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Norway", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Odds Ratio", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Probiotics", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Secondary Prevention", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Vagina", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Vaginosis, Bacterial", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Women's Health", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Obstetrics and Gynaecology, K\u00e4rnsjukhuset, SE-541 85, Sk\u00f6vde, Sweden", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Department of Obstetrics and Gynaecology, K\u00e4rnsjukhuset, SE-541 85, Sk\u00f6vde, Sweden"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Larsson", 
        "givenName": "Per-G\u00f6ran", 
        "id": "sg:person.012634564012.84", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012634564012.84"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Obstetrics and Gynaecology, University of Oslo, Norway Rikshospitalet/Radiumhospitalet, Oslo, Norway", 
          "id": "http://www.grid.ac/institutes/grid.5510.1", 
          "name": [
            "Department of Obstetrics and Gynaecology, University of Oslo, Norway Rikshospitalet/Radiumhospitalet, Oslo, Norway"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Stray-Pedersen", 
        "givenName": "Babill", 
        "id": "sg:person.0631122174.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0631122174.01"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Farmaservice, DK-2990, Niv\u00e5, Denmark", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Farmaservice, DK-2990, Niv\u00e5, Denmark"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ryttig", 
        "givenName": "Kjeld R", 
        "id": "sg:person.010725643124.05", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010725643124.05"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Norwegian School of Veterinary Science, also Ullev\u00e5l University Hospital, Oslo, Norway", 
          "id": "http://www.grid.ac/institutes/grid.19477.3c", 
          "name": [
            "Norwegian School of Veterinary Science, also Ullev\u00e5l University Hospital, Oslo, Norway"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Larsen", 
        "givenName": "Stig", 
        "id": "sg:person.013272512512.34", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013272512512.34"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2008-01-15", 
    "datePublishedReg": "2008-01-15", 
    "description": "BackgroundThe primary objective of this study was to investigate if supplementary lactobacilli treatment could improve the initial cure rate after vaginal clindamycin therapy, and secondly, if lactobacilli as repeated adjunct treatment during 3 menstrual cycles could lengthen the time to relapse after initial cure.MethodsWomen (n = 100) with bacterial vaginosis diagnosed by Amsel criteria were after informed consent offered vaginal clindamycin therapy followed by vaginal gelatine capsules containing either 109 freeze-dried lactobacilli or identical placebo capsules for 10 days during 3 menstrual cycles in a double-blind, randomized, placebo-controlled trial.ResultsThe initial intent to treat (ITT) analysis for the one-month cure rate was 64% in the lactobacilli group and 78% in the placebo group (p > 0.05). However, any patient with missing or unclassified smears at the initial visit who continued the study and whose next smear indicated a cure was included in the cured group; the study also excluded two of the patients in the lactobacilli group who reported that they did not take any vaginal capsules. With consideration to these population changes, the initial cure rate would be 77% in the lactobacilli group. The 76 cured women were followed for 6 menstrual cycles or until relapse within that time span. At the end of the study, 64.9% (24/37) of the lactobacilli treated women were still BV-free compared to 46.2% (18/39) of the placebo treated women. Comparison of the two groups regarding \"Time from cure to relapse\" was statistically significant (p = 0.027) in favour of the lactobacilli treatment. Adjuvant therapy with lactobacilli contributed significantly to avoidance of relapse with a proportional Hazard Risk ratio (HR) of 0.73 (0.54\u20130.98) (p < 0.05)ConclusionThe study shows that supplementary treatment combining two different strains of probiotic lactobacilli does not improve the efficacy of BV therapy during the first month of treatment, but for women initially cured, adjunct treatment of lactobacilli during 3 menstrual cycles lengthens the time to relapse significantly in that more women remained BV free at the end of the 6-month follow up.Trial registration numberISRCTN62879834", 
    "genre": "article", 
    "id": "sg:pub.10.1186/1472-6874-8-3", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1028438", 
        "issn": [
          "1472-6874"
        ], 
        "name": "BMC Women's Health", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "8"
      }
    ], 
    "keywords": [
      "hazard risk ratio", 
      "initial cure rate", 
      "menstrual cycle", 
      "cure rate", 
      "Lactobacillus treatment", 
      "clindamycin therapy", 
      "adjunct treatment", 
      "bacterial vaginosis", 
      "Lactobacillus group", 
      "identical placebo capsules", 
      "avoidance of relapse", 
      "placebo-controlled trial", 
      "placebo-controlled study", 
      "placebo capsules", 
      "placebo group", 
      "adjuvant therapy", 
      "initial visit", 
      "BV therapy", 
      "recurrence rate", 
      "Amsel criteria", 
      "risk ratio", 
      "vaginal capsules", 
      "supplementary treatment", 
      "therapy", 
      "first month", 
      "informed consent", 
      "relapse", 
      "patients", 
      "initial cure", 
      "women", 
      "more women", 
      "gelatine capsules", 
      "treatment", 
      "probiotic lactobacilli", 
      "vaginosis", 
      "cure", 
      "human lactobacilli", 
      "smears", 
      "Lactobacillus", 
      "capsule", 
      "primary objective", 
      "group", 
      "different strains", 
      "placebo", 
      "MethodsWomen", 
      "clindamycin", 
      "follow", 
      "study", 
      "trials", 
      "visits", 
      "supplementation", 
      "months", 
      "study show", 
      "efficacy", 
      "rate", 
      "initial intent", 
      "consent", 
      "days", 
      "time", 
      "criteria", 
      "intent", 
      "end", 
      "cycle", 
      "avoidance", 
      "strains", 
      "changes", 
      "BV", 
      "objective", 
      "favor", 
      "ratio", 
      "time span", 
      "comparison", 
      "analysis", 
      "span", 
      "consideration", 
      "population change", 
      "show"
    ], 
    "name": "Human lactobacilli as supplementation of clindamycin to patients with bacterial vaginosis reduce the recurrence rate; a 6-month, double-blind, randomized, placebo-controlled study", 
    "pagination": "3", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1005792714"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/1472-6874-8-3"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "18197974"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/1472-6874-8-3", 
      "https://app.dimensions.ai/details/publication/pub.1005792714"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-08-04T16:58", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/article/article_469.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1186/1472-6874-8-3"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/1472-6874-8-3'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/1472-6874-8-3'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/1472-6874-8-3'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/1472-6874-8-3'


 

This table displays all metadata directly associated to this object as RDF triples.

246 TRIPLES      20 PREDICATES      122 URIs      114 LITERALS      27 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/1472-6874-8-3 schema:about N00a61968459a45709af0a7a164059d91
2 N00db1f247225430c8e22f16fa9174fb7
3 N1e010c6039314b269700860fded61c7d
4 N2416aa67cab04e3bb9929460c34f3abe
5 N44de9aa8ed6f4951a71e705962c7068e
6 N479979b8fe974388a63afdd34340756a
7 N4c240cb674ea4d9b88ae2a4aac550968
8 N66eef0127cac4b069ce79e53945ebf4c
9 N7517a1ea74f94e9586fa65ffea616522
10 N79a98e9fd8b241cbabc2e8f2aac923ee
11 N7b9fef69ca97421190fe1e8e1d61ba75
12 N7e0dc1743c1b4dafacbd08a10dd81c80
13 N9033fc8f16b84dca9287e394c86348fa
14 N90837c2d6ada4283974cfacb3937916b
15 N91c550acd6464b4db288b99da9e59581
16 N9a534861d9414199956c4012f44d4faf
17 Naf5a25a3e88c43f5a552633786bc7d40
18 Nb25845f70db445f9b5f6997642756eb4
19 Nb5f4cd90797044a5933666334a01b390
20 Nc7ae757080304eb2a04a86772cbd69dd
21 anzsrc-for:11
22 anzsrc-for:1103
23 schema:author Nf682a0df54c24ae699508adff64980d1
24 schema:datePublished 2008-01-15
25 schema:datePublishedReg 2008-01-15
26 schema:description BackgroundThe primary objective of this study was to investigate if supplementary lactobacilli treatment could improve the initial cure rate after vaginal clindamycin therapy, and secondly, if lactobacilli as repeated adjunct treatment during 3 menstrual cycles could lengthen the time to relapse after initial cure.MethodsWomen (n = 100) with bacterial vaginosis diagnosed by Amsel criteria were after informed consent offered vaginal clindamycin therapy followed by vaginal gelatine capsules containing either 109 freeze-dried lactobacilli or identical placebo capsules for 10 days during 3 menstrual cycles in a double-blind, randomized, placebo-controlled trial.ResultsThe initial intent to treat (ITT) analysis for the one-month cure rate was 64% in the lactobacilli group and 78% in the placebo group (p > 0.05). However, any patient with missing or unclassified smears at the initial visit who continued the study and whose next smear indicated a cure was included in the cured group; the study also excluded two of the patients in the lactobacilli group who reported that they did not take any vaginal capsules. With consideration to these population changes, the initial cure rate would be 77% in the lactobacilli group. The 76 cured women were followed for 6 menstrual cycles or until relapse within that time span. At the end of the study, 64.9% (24/37) of the lactobacilli treated women were still BV-free compared to 46.2% (18/39) of the placebo treated women. Comparison of the two groups regarding "Time from cure to relapse" was statistically significant (p = 0.027) in favour of the lactobacilli treatment. Adjuvant therapy with lactobacilli contributed significantly to avoidance of relapse with a proportional Hazard Risk ratio (HR) of 0.73 (0.54–0.98) (p < 0.05)ConclusionThe study shows that supplementary treatment combining two different strains of probiotic lactobacilli does not improve the efficacy of BV therapy during the first month of treatment, but for women initially cured, adjunct treatment of lactobacilli during 3 menstrual cycles lengthens the time to relapse significantly in that more women remained BV free at the end of the 6-month follow up.Trial registration numberISRCTN62879834
27 schema:genre article
28 schema:isAccessibleForFree true
29 schema:isPartOf Nb2b488dd50494ead86b0369bd9eeedcf
30 Nfed393813e0340dfac4f13f42cd2c4d9
31 sg:journal.1028438
32 schema:keywords Amsel criteria
33 BV
34 BV therapy
35 Lactobacillus
36 Lactobacillus group
37 Lactobacillus treatment
38 MethodsWomen
39 adjunct treatment
40 adjuvant therapy
41 analysis
42 avoidance
43 avoidance of relapse
44 bacterial vaginosis
45 capsule
46 changes
47 clindamycin
48 clindamycin therapy
49 comparison
50 consent
51 consideration
52 criteria
53 cure
54 cure rate
55 cycle
56 days
57 different strains
58 efficacy
59 end
60 favor
61 first month
62 follow
63 gelatine capsules
64 group
65 hazard risk ratio
66 human lactobacilli
67 identical placebo capsules
68 informed consent
69 initial cure
70 initial cure rate
71 initial intent
72 initial visit
73 intent
74 menstrual cycle
75 months
76 more women
77 objective
78 patients
79 placebo
80 placebo capsules
81 placebo group
82 placebo-controlled study
83 placebo-controlled trial
84 population change
85 primary objective
86 probiotic lactobacilli
87 rate
88 ratio
89 recurrence rate
90 relapse
91 risk ratio
92 show
93 smears
94 span
95 strains
96 study
97 study show
98 supplementary treatment
99 supplementation
100 therapy
101 time
102 time span
103 treatment
104 trials
105 vaginal capsules
106 vaginosis
107 visits
108 women
109 schema:name Human lactobacilli as supplementation of clindamycin to patients with bacterial vaginosis reduce the recurrence rate; a 6-month, double-blind, randomized, placebo-controlled study
110 schema:pagination 3
111 schema:productId N3642e0ebb21040538bd6b3e426b28315
112 N89530cb1042548e38fd4e36680b7bee9
113 Ncc6bce085a9d490ea1ed98f92606f4b8
114 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005792714
115 https://doi.org/10.1186/1472-6874-8-3
116 schema:sdDatePublished 2022-08-04T16:58
117 schema:sdLicense https://scigraph.springernature.com/explorer/license/
118 schema:sdPublisher Nba3387338ea246f3b2cb92c7d2fd720c
119 schema:url https://doi.org/10.1186/1472-6874-8-3
120 sgo:license sg:explorer/license/
121 sgo:sdDataset articles
122 rdf:type schema:ScholarlyArticle
123 N00a61968459a45709af0a7a164059d91 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Follow-Up Studies
125 rdf:type schema:DefinedTerm
126 N00db1f247225430c8e22f16fa9174fb7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Vaginosis, Bacterial
128 rdf:type schema:DefinedTerm
129 N1e010c6039314b269700860fded61c7d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Norway
131 rdf:type schema:DefinedTerm
132 N204afa7100d64c7ab6f6164fca5b1798 rdf:first sg:person.0631122174.01
133 rdf:rest N94e1213285e64b3aa065fc508925a65b
134 N2416aa67cab04e3bb9929460c34f3abe schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Adult
136 rdf:type schema:DefinedTerm
137 N3642e0ebb21040538bd6b3e426b28315 schema:name dimensions_id
138 schema:value pub.1005792714
139 rdf:type schema:PropertyValue
140 N44de9aa8ed6f4951a71e705962c7068e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Confidence Intervals
142 rdf:type schema:DefinedTerm
143 N479979b8fe974388a63afdd34340756a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Administration, Oral
145 rdf:type schema:DefinedTerm
146 N4c240cb674ea4d9b88ae2a4aac550968 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Clindamycin
148 rdf:type schema:DefinedTerm
149 N66eef0127cac4b069ce79e53945ebf4c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Lactobacillus
151 rdf:type schema:DefinedTerm
152 N7517a1ea74f94e9586fa65ffea616522 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Probiotics
154 rdf:type schema:DefinedTerm
155 N79a98e9fd8b241cbabc2e8f2aac923ee schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
156 schema:name Administration, Intravaginal
157 rdf:type schema:DefinedTerm
158 N7b9fef69ca97421190fe1e8e1d61ba75 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
159 schema:name Female
160 rdf:type schema:DefinedTerm
161 N7e0dc1743c1b4dafacbd08a10dd81c80 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
162 schema:name Middle Aged
163 rdf:type schema:DefinedTerm
164 N89530cb1042548e38fd4e36680b7bee9 schema:name pubmed_id
165 schema:value 18197974
166 rdf:type schema:PropertyValue
167 N9033fc8f16b84dca9287e394c86348fa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
168 schema:name Double-Blind Method
169 rdf:type schema:DefinedTerm
170 N90837c2d6ada4283974cfacb3937916b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Humans
172 rdf:type schema:DefinedTerm
173 N91c550acd6464b4db288b99da9e59581 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name Secondary Prevention
175 rdf:type schema:DefinedTerm
176 N94e1213285e64b3aa065fc508925a65b rdf:first sg:person.010725643124.05
177 rdf:rest Nb5f524ba2e27458c83db25e6c21ec432
178 N9a534861d9414199956c4012f44d4faf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
179 schema:name Odds Ratio
180 rdf:type schema:DefinedTerm
181 Naf5a25a3e88c43f5a552633786bc7d40 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
182 schema:name Anti-Bacterial Agents
183 rdf:type schema:DefinedTerm
184 Nb25845f70db445f9b5f6997642756eb4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
185 schema:name Women's Health
186 rdf:type schema:DefinedTerm
187 Nb2b488dd50494ead86b0369bd9eeedcf schema:issueNumber 1
188 rdf:type schema:PublicationIssue
189 Nb5f4cd90797044a5933666334a01b390 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
190 schema:name Vagina
191 rdf:type schema:DefinedTerm
192 Nb5f524ba2e27458c83db25e6c21ec432 rdf:first sg:person.013272512512.34
193 rdf:rest rdf:nil
194 Nba3387338ea246f3b2cb92c7d2fd720c schema:name Springer Nature - SN SciGraph project
195 rdf:type schema:Organization
196 Nc7ae757080304eb2a04a86772cbd69dd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
197 schema:name Combined Modality Therapy
198 rdf:type schema:DefinedTerm
199 Ncc6bce085a9d490ea1ed98f92606f4b8 schema:name doi
200 schema:value 10.1186/1472-6874-8-3
201 rdf:type schema:PropertyValue
202 Nf682a0df54c24ae699508adff64980d1 rdf:first sg:person.012634564012.84
203 rdf:rest N204afa7100d64c7ab6f6164fca5b1798
204 Nfed393813e0340dfac4f13f42cd2c4d9 schema:volumeNumber 8
205 rdf:type schema:PublicationVolume
206 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
207 schema:name Medical and Health Sciences
208 rdf:type schema:DefinedTerm
209 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
210 schema:name Clinical Sciences
211 rdf:type schema:DefinedTerm
212 sg:journal.1028438 schema:issn 1472-6874
213 schema:name BMC Women's Health
214 schema:publisher Springer Nature
215 rdf:type schema:Periodical
216 sg:person.010725643124.05 schema:affiliation grid-institutes:None
217 schema:familyName Ryttig
218 schema:givenName Kjeld R
219 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010725643124.05
220 rdf:type schema:Person
221 sg:person.012634564012.84 schema:affiliation grid-institutes:None
222 schema:familyName Larsson
223 schema:givenName Per-Göran
224 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012634564012.84
225 rdf:type schema:Person
226 sg:person.013272512512.34 schema:affiliation grid-institutes:grid.19477.3c
227 schema:familyName Larsen
228 schema:givenName Stig
229 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013272512512.34
230 rdf:type schema:Person
231 sg:person.0631122174.01 schema:affiliation grid-institutes:grid.5510.1
232 schema:familyName Stray-Pedersen
233 schema:givenName Babill
234 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0631122174.01
235 rdf:type schema:Person
236 grid-institutes:None schema:alternateName Department of Obstetrics and Gynaecology, Kärnsjukhuset, SE-541 85, Skövde, Sweden
237 Farmaservice, DK-2990, Nivå, Denmark
238 schema:name Department of Obstetrics and Gynaecology, Kärnsjukhuset, SE-541 85, Skövde, Sweden
239 Farmaservice, DK-2990, Nivå, Denmark
240 rdf:type schema:Organization
241 grid-institutes:grid.19477.3c schema:alternateName Norwegian School of Veterinary Science, also Ullevål University Hospital, Oslo, Norway
242 schema:name Norwegian School of Veterinary Science, also Ullevål University Hospital, Oslo, Norway
243 rdf:type schema:Organization
244 grid-institutes:grid.5510.1 schema:alternateName Department of Obstetrics and Gynaecology, University of Oslo, Norway Rikshospitalet/Radiumhospitalet, Oslo, Norway
245 schema:name Department of Obstetrics and Gynaecology, University of Oslo, Norway Rikshospitalet/Radiumhospitalet, Oslo, Norway
246 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...